Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Common Equity: 2024-2025

Historic Common Equity for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $242.5 million.

  • Kura Oncology's Common Equity fell 42.77% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year decrease of 42.77%. This contributed to the annual value of $413.6 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Common Equity amounted to $242.5 million in Q3 2025, which was down 20.60% from $305.5 million recorded in Q2 2025.
  • Kura Oncology's Common Equity's 5-year high stood at $505.1 million during Q1 2024, with a 5-year trough of $242.5 million in Q3 2025.
  • Moreover, its 2-year median value for Common Equity was $413.6 million (2024), whereas its average is $388.7 million.
  • Data for Kura Oncology's Common Equity shows a maximum YoY slumped of 42.77% (in 2025) over the last 5 years.
  • Kura Oncology's Common Equity (Quarterly) stood at $413.6 million in 2024, then tumbled by 42.77% to $242.5 million in 2025.
  • Its Common Equity stands at $242.5 million for Q3 2025, versus $305.5 million for Q2 2025 and $364.4 million for Q1 2025.